**Amendments to original Tender No.:-BPPI/DRUG-016/2015 after Pre-Bid Meeting held on 13.02.2015 for supply of DRUGS & MEDICINES:-**

| S. No. | Page No | Clause | As in tender document | To be read as (Amended after pre-bid meeting held on 13.2.15) |
|---|---|---|---|---|
| I | 2,8& 9 | 1(a) 3(iii) | Last date for sale of tender documents: **20/02-2015 (Friday)** | Last date for sale of tender documents: *10/03/2015 (Tuesday)* |
| | | | Last date and time for receipt of tender documents: **02/03/2015 upto 12:00 Noon** | Last date and time for receipt of tender documents: *11/03/2015(Wednesday) upto 12:00 Noon* |
| | | | Time and date of opening of tender: **12:30 PM on 02/03/2015 (Monday)** | Time and date of opening of tender: *12:30 PM on 11/03/2015 (Wednesday)* |
| II | 8 | 2(a) | .....Distributors/Suppliers/Agents/Loan Licensees are not eligible to participate in the Tenders. | .....Distributors/Suppliers/Agents are not eligible to participate in the Tenders. Loan licensees are allowed provided the average annual turnover of bidding company should be at least Rs. 100 Crores for last 3 years and the average annual turnover of Host Firm (actual manufacturer) should be minimum Rs. 20 crores during the last 3 years. |
| | | 2(b) | Average Annual turnover in the last three years i.e. 2011-2012, 2012-2013 and 2013-14 shall not be less than **Rs. 20 Crores.** | Average Annual turnover in the last three years i.e. 2011-2012, 2012-2013 and 2013-14 shall not be less than **Rs. 20 Crores.** For loan licensees, average annual turnover should be at least 100 crores in last 3 years. |
| | | 2(c),(d),(e) | (a)(i)Black list<br>(ii)Blacklisted | ***(i) Blacklist/debar***<br>***(ii) Blacklisted/debarred*** |
| | | 2(c) | Tender should not be submitted for the product(s) for which the firm / company has been blacklisted by any State Government / Central Government / its Drug procurement agencies due to | Tender should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs *at the* |



Regd. Off.: Core No.6, First Floor, SCOPE Complex, Lodhi Road, New Delhi -110003
Divisional Off.: IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR) Ph.:- 0124-4303751, Fax:- 0124-2340370 &
Room No.304, 3rd Floor, 'B' Wing, Janpath Bhawan, Janpath, New Delhi-110 001

| | | | | |
|---|---|---|---|---|
| | | | quality failure of the drugs supplied in last 3 years. | *time of submission of tender documents.* |
| | | 2(d) | The Company/Firm which has been blacklisted by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting for last 3 years. | The Company/Firm which has been blacklisted/debarred by any State Government/Central Government / its Drug procurement agencies due to quality failure of the drugs supplied should not participate in the tender during the period of blacklisting/debarred *at the time of submission of tender documents.* |
| | | 2(e)(i) | The Tenderer should give a notarized affidavit that they have not been black listed due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **Annexure-IV**) for last 3 years. | The Tenderer should give a notarized affidavit that they have not been black listed/debarred due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies. (Notarized affidavit as per **Annexure-IV**) *at the time of submission of tender documents.* |
| | | 2(e)(ii) | During the validity of the tender if the firm / Company is blacklisted by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI by the tenderer firm/ company within one month. | During the validity of the tender if the firm / Company is *blacklisted/debarred* by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI by the tenderer firm/ company within one month. |
| | | 2(f) | | *Add Para 2(f)* f) Tenderer are required to incorporate bar codes as per GS1 standards at various packaging levels (primary, secondary and tertiary) Annexure XIX |
| III | 10 | 4.1 | The Tenderer should furnish the following documents in a separate cover hereafter called "Cover A". (All the documents submitted should be signed and sealed by the Tenderer in each page and photocopies of the documents should be attested by the | The Tenderer should furnish the following documents in a separate cover hereafter called "Cover A". (All the documents submitted should be signed and sealed by the Tenderer in each page and photocopies of the |

| | | | | |
|---|---|---|---|---|
| | | | Tenderer. All documents should also be notarized in each page) | documents should be attested by the Tenderer/***authorised person.*** |
| IV | 11 | 4.1(g) | Market Standing Certificate issued by the state Licensing Authority as a Manufacturer for each product quoted in the tender for a minimum 3 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be produced. | Market Standing Certificate (MSC) issued by the state Licensing Authority ***under generic or brand name*** as a Manufacturer for each product quoted in the tender for a minimum 3 years (Certificate should be enclosed with list of items). In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis are to be produced. ***MSC issued under brand name or under generic name (by the state licencing authority) will also be accepted but supplies will be accepted only in generic name*** |
| | | 4.1(h) | Performance statement of manufacture/import to establish market standing as per format in **Annexure-VII**. | Performance statement of manufacture/import to establish market standing as per format in **Annexure-VII**. ***In case of product manufactured at new location but not completed 3 years, Marketing certificate for 3 years for the product/s manufactured at two locations/factories of same manufacturer) will also be accepted.*** |
| | | 4.1(q) | Details of technical persons employed in the manufacturing and testing of drugs (employee name, qualification and experience) as endorsed in the license. | **Deleted and substituted with as under:** The loan license bidder are required to submit all the documents as per tender requirements for own manufacturing unit plus 20 crores average annual turnover of host company/actual manufacturer. |
| V | 15 | 7.2(vi) | Tenderer may be exempted from the payment of EMD, provided that requisite certificate from NSIC is produced. | Tenderer may be exempted from the payment of EMD, provided that requisite ***registration*** certificate from NSIC is produced ***for the product for which bidder has submitted quotation.*** |
| VI | 16 | 8.3 | Rates (inclusive of Customs duty, transportation, insurance, and any | Rates (inclusive of Customs duty, transportation, insurance, ***bar*** |

| | | | | |
|---|---|---|---|---|
| | | | incidental charges, but exclusive of CST/VAT (Sales Tax) and excise duty) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers. | ***coding*** and any incidental charges, but exclusive of CST/VAT (Sales Tax) and excise duty) should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers |
| VII | 17 | 9.1 | Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column6 - of **Annexure-XVII** and column 7 of **Annexure-XVIII**. As per Central Vigilance Commission guidelines, negotiations will be done with L1 bidder only. | Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done on the basis of rate per unit landed price as mentioned in column6 - of **Annexure-XVII** and column 7 of **Annexure-XVIII**. As per Central Vigilance Commission guidelines, negotiations will be done with L1 bidder ***if required.*** |
| VIII | 22 | 12.8 | Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015. | Tenderer should supply the product, within 2 months from the date of manufacture of that product. Products beyond 2 months from the date of manufacture shall not be accepted. For example product having manufacturing of April 2015 must be supplied before June 30, 2015. ***However for sterile products having shelf life of 18 months or more, products within 90 days (3 months) from date of manufacture will be accepted.***<br><br>***For imported products, 75% of shelf life should be available at time of supply.*** |

| | | | | |
|---|---|---|---|---|
| IX | 23, 24 | 14.3 | The packing in each carton shall be strictly as per the specification mentioned in Annexure-X. The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350 GSM. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label. | The packing in each carton shall be strictly as per the specification mentioned in Annexure-X. The outer carton should be of white board with a minimum of 300 GSM with ***Gloss laminated/UV varnished*** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350 GSM. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label. |
| X | 37 | Annexure 1 | Form or Certificate of Sales Tax verification to be Produced by an Application form the Contract or Other Patronage at the Disposal of The Government of India | Form or Certificate of Sales Tax verification ***(Performa of States as prescribed will also be accepted)*** |
| XI | 40 | Annex II- A | I / we do hereby declared that I will supply the drug and medicine by the Drugs and Medicine by affixing logo on Primary/Secondary/ Tertiary for the imported items along with the generic name as per the designs given in enclosures to this annexure and as per the instruction given in this regard. | I / we do hereby declared that I will supply the drugs and medicine by affixing logo on Primary/Secondary/Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure ***as well as other instructions*** given in this regard. |
| XII | 41-45 | | Manufactured for :<br><br>**Bureau of Public Sector Undertakings of India**<br>IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana) | Manufactured for :<br><br>**Bureau of *Pharma* Public Sector Undertakings of India**<br>IDPL Plant complex , Dundahera , Gurgaon 122016 (Haryana) |
| XIII | 44 | | Ointment / cream tube should be packed in mono carton (secondary packing ) with janaushadhi and BPPI logogram as given below. | Ointment / cream tube should be packed in mono carton (secondary packing ) with janaushadhi and BPPI logogram as given below. ***Logo in 4 colors will also be accepted (Only for tubes)*** |
| XIV | 46 to 54 | Annexure III | Annexure III | ***(i) following to be deleted from Declaration "I/We furnish the particulars in this regard in enclosure to this declaration"; (ii)Enclosure to Annexure III deleted(Page 47-54)*** |

| | | | | |
|---|---|---|---|---|
| XV | 55 | Annexure IV | I.....Managing Director/Partner/Proprietor of M/s. ..... having its manufacturing or import unit/ registered office at.....do hereby declare that our company/applied items have not been blacklisted either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender during last three years. We are eligible to participate in the tender ref. No. **BPPI/DRUG/016 Dt. 28-01-2015** for the following products. | I.....Managing Director/Partner/Proprietor of M/s. .....having its manufacturing or import unit/ registered office at.....do hereby declare that our company/applied items have not been blacklisted/debarred either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender. We are eligible to participate in the tender ref. No. **BPPI/DRUG/016 Dt. 28-01-2015** for the following products. |
| XVI | 58 | Annexure VII | Tabulation of Annexure VII [Total Column 1-6]<br><br>For a period of 05 years | ***The last column of table requiring name and full address of purchaser in annexure VII page 58 be deleted.*** [Total Column *1-5*]<br>Further following may be deleted " ***For a period of last 05 year"*** |
| XVII | 60,89 | Annexure IX,XVII, XVIII | Annexure IX,XVII,XVIII | ***Modified Annexure IX,XVII & XVIII has been replaced with original one with amendment in quantity, packaging etc. and addition of four products with Drug Code 25,53,194 & 197*** |
| XVIII | 60 | Product Code 117 | CHLORHEXIDINE MOUTHWASH IP 2 % w/v 160ml | CHLORHEXIDINE MOUTHWASH IP 2 % w/v<br><br>***100ml*** |
| XIX | 61 | Product Code 225 | IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /15 ML SYRUP | IRON HYDROXIDE POLYMALTOSE COMPLEX EQ TO ELEMENTAL IRON 50 MG+ FOLIC ACID 0.5 MG /*5* ML SYRUP |
| XX | 61 | Product Code 241 | COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM 10 MG /10 ML SYRUP<br><br>100 ml | COUGH SYRUP DEXTROMETHORPHAN HBR10 mg+ CPM *4* MG /10 ML SYRUP<br><br>100 ml |
| XXI | 62 | Product code 363 | GLARGINE 100 IU INJECTION<br><br>CARTRIDGE 3 ML | GLARGINE 100 IU INJECTION<br><br>CARTRIDGE/*VIAL* 3 ML |

| | | | | |
|---|---|---|---|---|
| XXII | 63 | Product Code 368 | GLICLAZIDE TABLETS SR 60 MG<br><br>14's | GLICLAZIDE TABLETS SR 60 MG<br><br>*10's* |
| XXIII | 64 | Product code 404 | LINEZOLID INFUSION 300 MG/200 ML<br><br>200 ML | LINEZOLID INFUSION *600* MG/*300* ML<br><br>***300 ML*** |
| XXIV | 65 | Product code 410 | TRASTUZUMAB INJECTION 400 MG | TRASTUZUMAB INJECTION *440* MG |
| XXV | 69 | Code 498 | FERROUS ASCORBATE TABLETS 1.1 MG | ***FERROUS ASCORBATE 100 MG(ELEMENTAL IRON) WITH FOLIC ACID 1.5MG TABLETS*** |
| XXVI | 72 | Product code 572 | COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS,PERTUSSIS,POLIOMYELITIS, AND HAEMOPHILUS INFLUENZA) INJECTION<br><br>5 ML | COMBINATIONS WITH TETANUS COMPONENT (DIPHTHERIA, TETANUS,PERTUSSIS,POLIOMYELITIS, AND HAEMOPHILUS INFLUENZA) INJECTION<br><br>*0.5* ML |
| XXVI I | 73 | Product code 579 | CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES | CALCIUM PANTOTHENATE 50MG+VIT B12 15 MCG+FOLIC ACID 1.5MG+THIAMINE MONONITRATE 10MG+RIBOFLAVINE 10MG+PYRIDOXINE HCL 3 MG+NIACINAMIDE 100 MG+ASCORBIC ACID 150MG +BIOTIN 100MCG CAPSULES<br>***Note: the participants having MSC of the product with same ingredients irrespective of the strength will be considered provided they have product permission as per tender. The product should be labelled as for therapeutic use as provided under Schedule V of drugs & Cosmetic Rules1945*** |
| XXVI II | 75 | 13 | The outer carton should be of white board with a minimum of 300 GSM with laminated packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM. | The outer carton should be of white board with a minimum of 300 GSM with ***Gloss laminated/UV Varnished*** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with white board of 350GSM. |

| | | | | |
|---|---|---|---|---|
| | | | CORRUGATED BOXES | CORRUGATED BOXES *(Liquid)* |
| XXIX | 87 | Point No. 10 of Annexure XVI | True copy of record of manufacture to establish 3 years market standing | ***Not Required*** |
| | 87 | Point 18. | Declaration form in Annexure III along with enclosures | Declaration form in Annexure III |
| | 88 | Point No.22 of Annexure XVI | Details of Technical personnel employed in the manufacture and testing | ***Not Required*** |
| | | Point No. 26 of Annexure XVI | | ***Add Point 26 Annexure XIX (Bar Coding)*** |
| XXX | | Point No. 27 of Annexure XVI | | ***Add point 27: Latest income tax assessment orders/return filed*** |